KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Change in Accured Expenses (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Change in Accured Expenses for 16 consecutive years, with $264000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 3200.0% to $264000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $264000.0, a 202.33% increase, with the full-year FY2025 number at $264000.0, up 202.33% from a year prior.
  • Change in Accured Expenses was $264000.0 for Q4 2025 at Biolife Solutions, down from $3.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.4 million in Q3 2025 to a low of -$3.7 million in Q4 2021.
  • A 5-year average of -$204650.0 and a median of $3500.0 in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: tumbled 14025.0% in 2024, then soared 338900.0% in 2025.
  • Biolife Solutions' Change in Accured Expenses stood at -$3.7 million in 2021, then skyrocketed by 92.89% to -$260000.0 in 2022, then skyrocketed by 788.08% to $1.8 million in 2023, then crashed by 99.55% to $8000.0 in 2024, then soared by 3200.0% to $264000.0 in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Change in Accured Expenses are $264000.0 (Q4 2025), $3.4 million (Q3 2025), and -$3.4 million (Q2 2025).